NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Détails

ID Serval
serval:BIB_B5E270CD6FAF
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
Périodique
Journal of the National Comprehensive Cancer Network
Auteur(s)
Haddad R.I., Nasr C., Bischoff L., Busaidy N.L., Byrd D., Callender G., Dickson P., Duh Q.Y., Ehya H., Goldner W., Haymart M., Hoh C., Hunt J.P., Iagaru A., Kandeel F., Kopp P., Lamonica D.M., McIver B., Raeburn C.D., Ridge J.A., Ringel M.D., Scheri R.P., Shah J.P., Sippel R., Smallridge R.C., Sturgeon C., Wang T.N., Wirth L.J., Wong R.J., Johnson-Chilla A., Hoffmann K.G., Gurski L.A.
ISSN
1540-1413 (Electronic)
ISSN-L
1540-1405
Statut éditorial
Publié
Date de publication
12/2018
Peer-reviewed
Oui
Volume
16
Numéro
12
Pages
1429-1440
Langue
anglais
Notes
Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.
Mots-clé
Antineoplastic Combined Chemotherapy Protocols/standards, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/analysis, Biomarkers, Tumor/genetics, Biomarkers, Tumor/metabolism, Carcinoma/diagnosis, Carcinoma/mortality, Carcinoma/pathology, Carcinoma/therapy, Clinical Trials as Topic, Humans, Image-Guided Biopsy/methods, Image-Guided Biopsy/standards, Medical Oncology/standards, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors/standards, Protein Kinase Inhibitors/therapeutic use, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Proto-Oncogene Proteins B-raf/genetics, Societies, Medical/standards, Thyroid Gland/diagnostic imaging, Thyroid Gland/pathology, Thyroid Gland/surgery, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/genetics, Thyroid Neoplasms/pathology, Thyroid Neoplasms/therapy, Thyroidectomy/methods, Thyroidectomy/standards, Treatment Outcome, United States
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/12/2020 22:51
Dernière modification de la notice
17/12/2020 7:26
Données d'usage